Colchicine and Post-COVID-19 Pulmonary Fibrosis
Impact of Colchicine on the Clinical Outcome of COVID-19 and the Development of Post-COVID-19 Pulmonary Fibrosis: Randomized Controlled Clinical Trial
Sponsor: ClinAmygate
This PHASE4 trial investigates Covid19 and Pulmonary Fibrosis Interstitial and is currently ongoing. ClinAmygate leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Unknown PHASE4
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Nov 2025 [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
-
Mar 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE4
▶ Show 4 earlier versions
-
Dec 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE4
Status: Completed → Active Not Recruiting
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE4
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE4
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ClinAmygate
For direct contact, visit the study record on ClinicalTrials.gov .